NEWS

EI-1071, Elixiron's drug candidate targeting microglia-induced inflammation for treating Alzheimer's disease has received the approval for a clinical trial in Taiwan

EI-001, Elixiron's drug candidate for treating vitiligo, has received approval for a clinical trial in China from the National Medical Products Administration

Elixiron partners with Yang-Ming University to jointly develop new immunotherapy technology for head and neck cancer - novel drug combining tumor macrophage-targeting antibody with interleukin-10 fusion protein

A new mechanism of IFN-γ in the pathogenesis of vitiligo reveald by a discovery from the collaborative research of Chang-Gung University and Elixiron

Elixiron Biotherapeutics Secures 2022 Part the Cloud Grant to Advance EI-1071 into Phase II Trials

Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to Interferon-Gamma-Neutralizing Antibody, EI 001 for the Treatment of Hemophagocytic Lymphohistiocytosis

Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis

Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response

Elixiron Immunotherapeutics Receives Grant from the Alzheimer’s Association to Trial Microglia-Targeting Immunotherapy

Elixiron dives into IFNγ and CSF-1R with pathway-centric approach

Nature | Chen Ting’s Research Team Unveils How Fibroblasts Regulate the Onset of Autoimmune Skin Diseases

A bifunctional anti-PD-L1 antibody/IL-10 fusion protein targeting exhausted T cells for cancer immunotherapy